Tesofensine 500mcg (30 Capsules)

Description

What is Tesofensine?

Tesofensine represents a synthetic small-molecule compound with unique research potential. This compound functions as a triple monoamine reuptake inhibitor. Researchers designate the compound as NS-2330 in scientific literature. The compound targets three major neurotransmitter systems simultaneously.
The phenyltropane-derived structure distinguishes Tesofensine from other compounds. This structural classification influences its binding properties and effects. Unlike peptides, NS-2330 functions as a synthetic organic molecule. The molecular weight of 328.3 g/mol allows for efficient distribution in research models.
Tesofensine operates through complete inhibition of monoamine transporters. The compound blocks dopamine, norepinephrine, and serotonin reuptake. This triple action creates extensive modulation of monoaminergic pathways. Researchers value this comprehensive approach for studying neurotransmitter dynamics.
The 500mcg capsule format provides precise dosing control for researchers. Each bottle contains 30 capsules, allowing for many study durations. The low dosage strength allows titration and dose-response studies. Researchers can easily adjust dosing based on experimental requirements.

Understanding Triple Monoamine Reuptake Inhibition

Monoamine transporters regulate neurotransmitter levels in the brain. These transporters remove dopamine, norepinephrine, and serotonin from synapses. Inhibition of these transporters increases neurotransmitter availability. This compound targets all three major monoamine transporters simultaneously.
Dopamine transporter inhibition increases synaptic dopamine levels. Dopamine influences reward, motivation, and movement. Enhanced dopamine signaling affects many behavioral and physiological processes. Researchers study these effects in many experimental models.
Norepinephrine transporter inhibition elevates norepinephrine levels. This neurotransmitter regulates attention, arousal, and energy expenditure. Increased noradrenergic signaling influences metabolic processes and cardiovascular function. Tesofensine’s effects on norepinephrine add to its metabolic research applications.
Serotonin transporter inhibition raises serotonin levels in synapses. Serotonin modulates mood, appetite, and many other functions. Enhanced serotonin signaling affects feeding behavior and emotional control. The compound’s complete inhibition addresses multiple aspects of monoaminergic signaling.
Triple reuptake inhibitors represent an advanced pharmacological approach. Single transporter inhibitors like SSRIs target only serotonin. Dual inhibitors address two neurotransmitter systems. Tesofensine’s triple action provides more comprehensive modulation. Visit the Research Hub to learn more about monoamine transporters.

Tesofensine’s Mechanism in Energy Metabolism

The compound shows significant effects on energy metabolism in lab studies. The compound influences multiple metabolic pathways simultaneously. Energy expenditure increases through norepinephrine-mediated mechanisms. This effect adds to the compound’s weight loss research potential.
Appetite control represents another key metabolic effect. Tesofensine suppresses appetite through indirect receptor activation. Alpha1 adrenoceptors and dopamine D1 receptors mediate these effects. The combined monoamine increase creates strong appetite suppression. Researchers study these mechanisms for obesity treatment research.
Glycemic control improves with NS-2330 in experimental models. The compound enhances insulin response and glucose control. These effects extend beyond simple appetite suppression. Metabolic research studies Tesofensine’s comprehensive effects on glucose homeostasis.
Fat oxidation increases with Tesofensine treatment in animal studies. The compound promotes use of stored fat for energy. This effect adds to weight loss and body composition changes. Researchers study fat metabolism pathways to understand the compound’s metabolic actions.
Energy balance control involves both intake and expenditure. Tesofensine addresses both sides of this equation. Appetite suppression reduces caloric intake. Increased energy expenditure burns stored energy. This dual approach creates full metabolic effects in research models.

Research Applications in Weight Loss Studies

The molecule shows exceptional promise in weight loss research applications. Lab studies show substantial weight reduction effects. The compound produces weight loss about 2-3 times greater than sibutramine. In the 24-week TIPO-1 Phase 2 trial, daily doses of Tesofensine 0.25 mg, 0.5 mg, and 1 mg produced dose-dependent weight loss over 24 weeks, with the higher doses far exceeding placebo. This high potency makes the molecule a subject of intense study.
Obesity research incorporates Tesofensine in many experimental models. Diet-induced obese rats show significant weight reduction with treatment. The compound reduces both fat mass and overall body weight. These effects persist throughout treatment periods in research studies.
Body makeup research reveals preferential fat loss effects. The compound reduces adipose tissue while preserving lean mass. This selective fat loss improves body makeup in experimental models. Researchers study the mechanisms underlying this selective fat reduction.
Phase 3 clinical trials have studied Tesofensine in obese patients. These trials showed significant weight loss with treatment. The compound met primary and secondary efficacy endpoints. Research continues to optimize dosing and safety profiles for potential therapeutic applications.
Parkinson’s and Alzheimer’s disease patients showed unexpected weight loss in early studies. This serendipitous discovery led to focused obesity research. The weight loss effects proved substantial in patient populations. These findings prompted comprehensive study of the compound’s metabolic properties.

Neurotrophic Effects and BDNF Expression

Tesofensine shows significant neurotrophic effects in lab studies. The compound enhances expression of brain-derived neurotrophic factor (BDNF). BDNF plays crucial roles in neuronal survival, growth, and plasticity. Researchers study the compound’s effects on BDNF for neuroprotection research.
Hippocampal neurogenesis increases with Tesofensine treatment. Adult rats show enhanced neurogenesis after chronic administration. New neuron formation in the hippocampus supports cognitive function. Researchers study these effects for depression and cognitive disorder research.
Activity-regulated cytoskeleton protein expression responds to Tesofensine. This protein supports synaptic plasticity and neuronal adaptation. Enhanced expression shows improved neuronal function and adaptability. These neurotrophic effects complement the compound’s monoaminergic actions.
Antiapoptotic effects have been observed in research studies. Tesofensine may protect neurons from programmed cell death. This neuroprotective property extends beyond monoaminergic stimulation. Researchers study these effects for neurodegenerative disease applications.
Transcriptomic analyses reveal differential gene expression patterns. Tesofensine treatment alters expression of neurotrophic and metabolic genes. These changes support the compound’s observed biological effects. Molecular research continues to study gene expression patterns.

Dopaminergic Pathway Modulation

The compound’s effects on dopaminergic pathways represent a key research area. Dopamine transporter inhibition increases synaptic dopamine availability. Enhanced dopamine signaling affects reward, motivation, and movement pathways. Researchers study these effects in many behavioral and cognitive models.
Dopamine D1 receptor activation mediates some Tesofensine effects. The compound indirectly activates these receptors through increased dopamine. D1 receptor activation influences appetite control and reward processing. Appetite suppression effects partly depend on this dopaminergic pathway.
Behavioral research studies the compound’s effects on motivation and reward. Increased dopamine availability may enhance motivation and goal-directed behavior. These effects have implications for depression and addiction research. Studies examine how Tesofensine influences reward-related behaviors.
Motor function research also incorporates dopaminergic effects. Dopamine plays crucial roles in movement coordination and control. The compound’s dopaminergic stimulation may affect motor performance. Researchers study these effects in Parkinson’s disease models and other movement disorders.
Comparative studies examine Tesofensine versus other dopaminergic compounds. The triple reuptake inhibition provides unique benefits over dopamine-specific agents. Researchers compare efficacy, safety, and side effect profiles. These comparisons inform possible therapeutic applications.

Noradrenergic and Serotonergic Effects

The compound’s noradrenergic effects add greatly to its profile. Norepinephrine transporter inhibition elevates synaptic norepinephrine levels. Increased noradrenergic signaling affects attention, arousal, and energy metabolism. These effects support Tesofensine’s metabolic and weight-loss research applications.
Energy expenditure increases through norepinephrine-mediated mechanisms. Norepinephrine increases thermogenesis and lipolysis in adipose tissue. This metabolic effect adds to weight loss observed in studies. Researchers study the specific pathways involved in norepinephrine-induced energy expenditure.
Attention and cognitive function benefit from noradrenergic stimulation. Norepinephrine improves focus, alertness, and cognitive performance. The compound’s noradrenergic effects may enhance cognitive function in research models. Studies examine possible applications for attention disorders and cognitive enhancement.
Serotonergic effects complement Tesofensine’s dopaminergic and noradrenergic actions. Serotonin transporter inhibition increases synaptic serotonin levels. Enhanced serotonin signaling affects mood, appetite, and emotional control. The combination of three monoamines creates full neurotransmitter modulation.
Mood-related research studies the compound’s serotonergic effects. Increased serotonin availability may alleviate depressive symptoms. Triple reuptake inhibition offers benefits for depression treatment research. Studies compare Tesofensine to traditional antidepressants targeting single transporters.

Dosage Protocols and Administration

This compound dosing requires careful consideration based on research objectives. The 500mcg capsule strength provides flexibility in protocol design. Research protocols often use dosages ranging from 500mcg to 1mg daily, with clinical studies also evaluating a lower Tesofensine 0.25 mg reference dose. The 30-capsule bottle supports many dosing strategies for studies of different durations.
Dosing frequency depends on specific research goals. Most protocols use once-daily dosing due to the compound’s prolonged half-life. The sustained effects allow convenient single daily dosing in research studies. This dosing frequency supports compliance in longer-term protocols.
Timing of administration may influence research outcomes. Morning administration often aligns with circadian patterns of monoamine activity. Some studies prefer administration before meals to maximize appetite suppression effects. Best timing depends on the specific research endpoints under study.
Capsule administration offers convenient oral delivery of Tesofensine. The 500mcg strength provides precise dose control for research protocols. Oral absorption allows systemic administration without injection requirements. Researchers can easily track compliance with capsule-based administration.
Dose titration protocols may be appropriate for certain research designs. Starting with lower doses and gradually increasing allows assessment of personal responses. The 500mcg capsule strength helps precise titration steps. Researchers establish clear titration schedules and monitoring protocols.
Use our Peptide Calculator to find best dosing for your research protocol. Note that while designed for peptides, the calculator principles apply to dosing calculations for the molecule as well.

Tesofensine Safety Profile and Side Effects

Research on Tesofensine reveals important safety factors. Clinical trials showed significant weight loss effects but also identified side effects. Understanding the safety profile is crucial for research design and interpretation.
Cardiovascular effects represent a primary safety consideration. Increased norepinephrine can elevate heart rate and blood pressure. Clinical trials reported dose-dependent increases in these parameters. Researchers monitor cardiovascular endpoints closely in the compound studies.
Central nervous system effects include many symptoms. Insomnia, dry mouth, and headache have been reported in clinical studies. These effects relate to the compound’s monoaminergic stimulation properties. Most CNS side effects appear dose-dependent and may diminish over time.
Gut effects occur in some research subjects. Nausea, constipation, and other digestive symptoms have been observed. These effects often remain mild to moderate in severity. Research protocols track gut symptoms as part of safety monitoring.
Safety data from Parkinson’s and Alzheimer’s studies provided initial insights. Weight loss emerged as an unexpected effect in these early studies. Researchers noted side effects that informed later obesity trial designs. These early safety findings guided dosing and monitoring protocols.
Adverse event reporting requires careful consideration in research. Some studies reported initial under-reporting of side effects. Full safety monitoring is essential for accurate adverse event capture. Researchers use systematic monitoring of all potential side effects.

Comparative Research to Other Compounds

Tesofensine shows unique properties compared to other weight loss compounds. Comparisons to sibutramine reveal about 2-3 times greater potency. This enhanced efficacy makes NS-2330 an important compound for obesity research.
Sibutramine functions mainly as a serotonin-norepinephrine reuptake inhibitor. Tesofensine adds dopamine reuptake inhibition to create triple action. This more dopaminergic component may contribute to enhanced efficacy. Researchers study how triple inhibition differs from dual inhibition approaches.
Rimonabant comparisons focus on different mechanisms of action. Rimonabant targets cannabinoid receptors rather than monoamine transporters. The compound’s monoaminergic approach provides distinct benefits and disadvantages. Comparative studies examine efficacy and safety profiles of both compounds.
Traditional antidepressants offer important comparison points. SSRIs target only serotonin reuptake. SNRIs block serotonin and norepinephrine. Tesofensine’s triple reuptake inhibition provides more comprehensive modulation. Researchers study possible uses for depression treatment research.
Tricyclic antidepressants share some properties with the molecule. These older compounds affect multiple neurotransmitter systems but with less selectivity. Tesofensine’s more targeted triple reuptake inhibition may offer improved safety profiles. Comparative pharmacology studies examine these differences in detail.

Combination Protocols with Metabolic Compounds

The compound may be combined with other body research compounds. Combination approaches can target multiple pathways simultaneously. This strategy may provide combined benefits beyond single-compound use in research models.
Metabolic peptides like MOTS-C 40mg complement Tesofensine’s actions. MOTS-C improves mitochondrial function and glucose metabolism. Enhanced cellular energy production supports metabolic processes. The combination addresses both neurotransmitter signaling and cellular energy metabolism.
NAD+ boosters like NAD+ 1000mg support cellular repair processes. NAD+ participates in many metabolic reactions including energy production. Enhanced NAD+ levels may support metabolic support alongside the compound’s effects. This combination addresses cellular metabolism and neurotransmitter modulation.
5-Amino-1MQ works through different metabolic pathways. This compound inhibits NNMT to raise NAD+ levels and enhance metabolic function. Combining with Tesofensine may provide complementary effects on weight control. The combination addresses neurotransmitter signaling and NAD+-dependent metabolic pathways.
Appetite suppression compounds may offer more research insights. Peptides or other compounds affecting hunger pathways could complement the compound’s effects. Research examines whether combination approaches enhance weight loss beyond monotherapy. These combinations require careful evaluation of potential interactions.
Combination protocols require careful consideration of dosing and timing. Researchers must assess potential interactions between compounds. Separate use times may optimize absorption and minimize potential competition. The 500mcg capsule format helps precise combination dosing protocols.

Preclinical Research Summary and Future Directions

Lab studies reveal extensive Tesofensine research findings. Rodent models show significant effects on neurotransmitter dynamics. Behavioral studies show changes in activity, feeding, and metabolic parameters. These lab results support continued study of the compound’s potential.
Transcriptomic and proteomic analyses provide molecular-level insights. Differential expression patterns emerge in neurotrophic and metabolic genes. These molecular-level changes correlate with observed biological effects. Research continues to map complete gene expression profiles following Tesofensine treatment.
Phase 3 clinical trials represent advanced study stages. Tesofensine met primary and secondary endpoints in obesity registration trials. These trials showed significant weight loss with acceptable safety profiles. Research continues to optimize treatment windows and dosing strategies.
Neurodegenerative disease research incorporates the compound’s neurotrophic effects. BDNF upregulation and hippocampal neurogenesis suggest potential applications. Studies investigate Tesofensine for depression, cognitive impairment, and neurodegenerative conditions. These applications extend beyond metabolic research.
Personalized medicine approaches may benefit from NS-2330 research. Major depression presents with varying symptoms and treatment responses. Tesofensine’s triple reuptake inhibition may address multiple symptom domains. Research examines personal differences in response to comprehensive monoaminergic modulation.
Future research directions include mechanism refinement and safety optimization. Understanding the precise pathways involved in the compound’s effects remains ongoing. Researchers study receptor subtypes, signaling cascades, and downstream effects. This knowledge will inform potential therapeutic applications and safety profiles.

Frequently Asked Questions

1. What is Tesofensine and how does it work as a triple reuptake inhibitor?

Tesofensine (NS-2330) is a synthetic phenyltropane-derived compound that functions as a novel triple monoamine reuptake inhibitor. The compound simultaneously blocks dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT). This complete inhibition increases synaptic availability of all three major monoamines. Tesofensine’s effects extend beyond simple neurotransmitter increase to include appetite suppression through alpha1 adrenoceptor and dopamine D1 receptor pathways, enhanced BDNF expression, and increased hippocampal neurogenesis. The triple action provides more comprehensive modulation than single or dual reuptake inhibitors.

2. What are the primary research applications of Tesofensine?

The molecule shows significant research potential across multiple domains including weight loss and obesity research, energy metabolism studies, appetite control studies, and neurotrophic factor expression studies. Lab studies show about 2-3 times greater weight-loss efficacy compared to sibutramine. Additional applications include glycemic control research, fat metabolism studies, depression studies due to neurotrophic effects, and cognitive function research. The compound’s comprehensive monoaminergic modulation makes it valuable for studying integrated neurotransmitter systems and their effects on metabolic function and behavior.

3. What is the recommended Tesofensine dosage for research studies?

Most research protocols use Tesofensine dosages ranging from 500mcg to 1mg daily. The 500mcg capsule strength provides flexibility for protocol design and dose titration. Due to the compound’s prolonged half-life, most protocols recommend once-daily dosing. The 30-capsule bottle provides enough supply for many study durations depending on dosing frequency. Morning administration often aligns with circadian patterns of monoamine activity, though best timing depends on specific research endpoints. Always consult established research protocols and use our Peptide Calculator to find best dosing for your specific study design.

4. How does Tesofensine compare to other weight loss compounds like sibutramine or rimonabant?

The compound shows about 2-3 times greater potency than sibutramine in inducing weight loss. While sibutramine functions as a serotonin-norepinephrine reuptake inhibitor, Tesofensine adds dopamine reuptake inhibition to create triple action. This more dopaminergic component may contribute to enhanced efficacy. Compared to rimonabant which targets cannabinoid receptors, NS-2330 uses monoaminergic pathways with distinct mechanisms and side effect profiles. Lab studies show Tesofensine produces sustained weight loss and improves glycemic control more effectively than both sibutramine and rimonabant in diet-induced obese rat models.

5. What are the potential side effects of Tesofensine in research studies?

Clinical trials identified several side effects requiring careful monitoring. Cardiovascular effects include dose-dependent increases in heart rate and blood pressure due to norepinephrine increase. Central nervous system effects include insomnia, dry mouth, and headache related to monoaminergic stimulation. Gut effects such as nausea and constipation have been reported in some subjects. Researchers use comprehensive safety monitoring including cardiovascular assessment, CNS symptom monitoring, and adverse event reporting. Some studies noted initial under-reporting of side effects, emphasizing the need for systematic safety monitoring protocols.

6. What neurotrophic effects does Tesofensine demonstrate in preclinical studies?

This compound shows significant neurotrophic effects beyond its monoaminergic actions. The compound enhances expression of brain-derived neurotrophic factor (BDNF), which plays crucial roles in neuronal survival, growth, and plasticity. Studies show enhanced adult hippocampal neurogenesis following sub-chronic and chronic Tesofensine treatment. Activity-regulated cytoskeleton protein expression increases, supporting synaptic plasticity and neuronal adaptation. Antiapoptotic effects protect neurons from programmed cell death. Transcriptomic analyses reveal differential expression patterns in neurotrophic and metabolic genes, supporting the compound’s comprehensive biological effects.

7. How does Tesofensine influence appetite regulation and energy metabolism?

Tesofensine suppresses appetite through indirect activation of alpha1 adrenoceptors and dopamine D1 receptors. The combined increase of dopamine, norepinephrine, and serotonin creates strong appetite suppression effects. Energy metabolic rate increases through norepinephrine-mediated thermogenesis and lipolysis in adipose tissue. Glycemic control improves with enhanced insulin response and glucose control. The compound promotes fat oxidation and preferential fat loss while preserving lean mass. This dual approach of reducing intake through appetite suppression and increasing expenditure through enhanced metabolic function creates full metabolic effects.

8. Can Tesofensine be combined with other metabolic research compounds?

Yes, the molecule may be combined with other metabolic research compounds to target multiple pathways simultaneously. Combining with MOTS-C 40mg addresses both neurotransmitter signaling and cellular energy metabolism through mitochondrial stimulation. NAD+ 1000mg supports cellular repair processes alongside Tesofensine’s metabolic effects. 5-Amino-1MQ provides paired NNMT inhibition and NAD+ elevation for comprehensive metabolic modulation. Combination protocols require careful consideration of dosing, timing, and potential interactions. The 500mcg capsule format helps precise combination dosing for research studies.

9. What distinguishes Tesofensine from traditional antidepressants?

The compound differs from traditional antidepressants through its full triple reuptake inhibition. SSRIs target only serotonin reuptake, while SNRIs block serotonin and norepinephrine. Tesofensine adds dopamine reuptake inhibition to create complete monoaminergic modulation. This triple action may address multiple symptom domains in depression and other conditions. Also, the compound’s major metabolic effects and weight loss properties distinguish it from traditional antidepressants, which often cause weight gain. The compound’s neurotrophic effects including BDNF upregulation and hippocampal neurogenesis provide more benefits beyond simple neurotransmitter increase.

10. What are the storage requirements for Tesofensine 500mcg capsules?

Tesofensine capsules should be stored in a cool, dry location away from direct sunlight to maintain potency and stability. Room temperature storage (15-25°C or 59-77°F) is often enough for short-term storage during active research protocols. For longer storage periods, refrigeration (2-8°C or 36-46°F) may help extend shelf life and preserve compound stability. Always keep capsules in their original container with the lid tightly closed to protect from moisture and humidity. Avoid storing in bathrooms or other humid environments. Do not freeze the capsules. Check expiration dates and discard capsules showing signs of breakdown or discoloration.

11. How long does it take to see Tesofensine effects in research subjects?

Research suggests Tesofensine’s effects on appetite and metabolic function may emerge within the first week of administration. Weight loss effects often become measurable within 2-4 weeks of consistent treatment in lab models. Neurotrophic effects including BDNF expression and hippocampal neurogenesis may require 4-8 weeks of chronic treatment to manifest fully. Pivotal clinical work measured outcomes over 24 weeks, and the compound’s prolonged half-life supports sustained effects with once-daily dosing. Research protocols should account for these different timelines when designing study schedules and outcome measurements. Behavioral and metabolic effects appear more rapidly than neurotrophic and gene expression changes.

12. What makes Tesofensine unique among triple reuptake inhibitors?

The compound’s uniqueness stems from its phenyltropane-derived structure and exceptional potency. The compound shows about 2-3 times greater weight-loss efficacy than other monoamine reuptake inhibitors like sibutramine. Unlike many other triple reuptake inhibitors, Tesofensine has progressed through Phase 3 clinical trials for obesity, demonstrating significant efficacy in human studies. The compound’s comprehensive effects on metabolic function, appetite, neurotrophic factors, and glycemic control create a unique research profile. The serendipitous discovery of weight loss effects in Parkinson’s and Alzheimer’s disease patients led to focused investigation not seen with other compounds in this class.